Erlotinib Recruiting Phase 1 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02991651Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
NCT03050411Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer